Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy

Melanoma patients harbouring BRAFV600E mutation generally develop resistance to targeted therapy. In this study, the authors demonstrate that SREBP-1-mediated induction of lipid biosynthesis contributes to therapy resistance in BRAF mutant melanoma.

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Ali Talebi, Jonas Dehairs, Florian Rambow, Aljosja Rogiers, David Nittner, Rita Derua, Frank Vanderhoydonc, Joao A. G. Duarte, Francesca Bosisio, Kathleen Van den Eynde, Kris Nys, Mónica Vara Pérez, Patrizia Agostinis, Etienne Waelkens, Joost Van den Oord, Sarah-Maria Fendt, Jean-Christophe Marine, Johannes V. Swinnen
Format:	article
Langue:	EN
Publié:	Nature Portfolio 2018
Sujets:	Science Q
Accès en ligne:	https://doaj.org/article/c1bb7bfd70be4f42827f1d7f1e16991f
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!

Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy

Documents similaires